|
|
|
|
|
Metipranolol
drug data and news
Metipranolol drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Metipranolol | ||
| Brand Names/Synonyms | BRN 2152010; Disorat; METIPRANOLOL HYDROCHLORIDE; Metipranolol; Metipranolol [Usan:Ban:Inn]; Metipranololum [Inn-Latin]; Optipranolol; Trimepranol; VUFB-6453 | ||
| Indication | Indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Metipranolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Metipranolol is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Metipranolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Metipranolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce. | ||
| Mechanism Of Action | Although it is known that metipranolol binds the beta1 and beta2 adrenergic receptors, the mechanism of metipranolol's action is not known. It has no significant intrinsic sympathomimetic activity, and has only weak local anesthetic (membrane-stabilizing) and myocardial depressant activity. It appears that the ophthalmic beta-adrenergic blocking agents reduce aqueous humor production, as demonstrated by tonography and fluorophotometry. A slight increase in aqueous humor outflow may be an additional mechanism. | ||
| Metipranolol News (When available) |
| ||
| Dosage Forms | Not Available | ||
| Drug_Category | Adrenergic beta-Antagonists; Sympatholytics; Antihypertensive Agents; Anti-Arrhythmia Agents; ATC:S01ED04 | ||
| Absorption | Not Available | ||
| Interactions |
-->Interactions for Metipranolol: OptiPranolol® Ophthalmic Solution should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally, because of the potential for additive effects on systemic beta-blockade. Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or bradycardia. Caution should be used in the coadministration of beta-adrenergic receptor blocking agents, such as metipranolol, and oral or intravenous calcium channel antagonists, because of possible precipitation of left ventricular failure, and hypotension. In patients with impaired cardiac function, who are receiving calcium channel antagonists, coadministration should be avoided. The concomitant use of beta-adrenergic receptor blocking agents with digitalis and calcium channel antagonists may have additive effects, prolonging atrioventricular conduction time. Caution should be used in patients using concomitant adrenergic psychotropic drugs. Ocular In patients with angle-closure glaucoma, the immediate treatment objective is to re-open the angle by constriction of the pupil with a miotic agent. OptiPranolol Ophthalmic Solution has little or no effect on the pupil, therefore, when it is used to reduce intraocular pressur e in angle-closure glaucoma, it should be used only with concomitant administration of a miotic agent. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | [4-[2-hydroxy-3-(1-methylethylamino)propoxy]-2,3,6-trimethyl-phenyl]ethanoate | ||
| Chemical Formula | C17H27NO4 | ||
| Molecular Weight | 309.401 g/mol | ||
| Smiles String | CC1=CC(=C(C(=C1OC(=O)C)C)C)OCC(CNC(C)C)O | ||
| Melting Point | 105-107 °C | ||
| Water Solubility | 589 mg/L | ||
| State | Solid (white, odorless, crystalline powder) | ||
| LogP/Hphobicity | 3.034 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | Not Available | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Metipranolol.html http://www.rxlist.com/cgi/generic3/optipran.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00668 | ||
| CAS Registry Number | 22664-55-7 | ||
| KEGG Compound ID | C07915 | ||
| PubChem ID | SID:10117 | ||
| PharmGKB ID | PA450473 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |